122 results about "Coagulation system" patented technology

Aspects of the present disclosure include an attachable power and control system to supply energy to electrodes of a wiping electrode coagulation system of a surgical device. A surgical device includes electrodes at an end of effector to aide in sealing during various surgical procedures. During the procedure, the surgeon may wipe the surgical site with the end effector, causing the electrodes to touch the fractured area. Electrosurgical energy may be applied to the electrodes during the wiping, causing coagulation of smaller vessels. The attachable power and control system may be configured to slide over the shaft of the surgical device. The power and control system also may be configured to supply power to the electrodes and to control when energy is applied to the electrodes, based in part, for example, on measuring a distance or angle of the opening of the jaws at the end effector.

Aspects of the present disclosure include an attachable power and control system to supply energy to electrodes of a wiping electrode coagulation system of a surgical device. A surgical device includes electrodes at an end of effector to aide in sealing during various surgical procedures. During the procedure, the surgeon may wipe the surgical site with the end effector, causing the electrodes to touch the fractured area. Electrosurgical energy may be applied to the electrodes during the wiping, causing coagulation of smaller vessels. The attachable power and control system may be configured to slide over the shaft of the surgical device. The power and control system also may be configured to supply power to the electrodes and to control when energy is applied to the electrodes, based in part, for example, on measuring a distance or angle of the opening of the jaws at the end effector.

Disclosed herein are wound dressings comprising fibrinogen and at least one procoagulant such as propyl gallate in a therapeutic amount. Also disclosed are methods of treating wounds, increasing an amount of or rate of coagulation of blood from a wound, increasing an amount of or rate of clot formation over a wound, increasing blood platelet counts, activating a coagulation system, increasing the plasma concentration of fibrinogen, and decreasing the activated partial thromboplastin time. Also disclosed are an arterial bleeding model and methods of studying arterial bleeding.

Provided is a standalone integrated water treatment system for a distributed water supply. A filter input receives water to be treated. A coagulation system is in operative connection with the filter input, wherein the water which has been filtered is subjected to a coagulation process performed by the coagulation system to create pin floc from suspensions in the water. A maturation buffer tank is in operative connection with the coagulation system, wherein floc is aggregated in size within the water. A spiral separator is in operative connection with the maturation buffer tank, and the water is separated into two water streams, a first stream of water having most of the floc removed, and a second stream of water which includes a concentrated amount of the floc. An optional filtration system is in operative connection with the spiral separator and is configured to receive the first stream of water and to perform a filtration operation on the first stream of water. A sterilization system is in operative connection with the optional filtration system and is configured to perform a sterilization operation on the first stream of water. The water is then output from the sterilization system as potable water.

The present invention provides novel compounds of formula 1a, novel compositions, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPase's) such as PTP1B, CD45, SHP-1, SHP-2, PTPα, LAR and HePTP or the like. The compounds are useful in the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, immune dysfunctions including autoimmunity diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of / or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases.

The present invention provides novel compounds, novel compositions, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPases) such as PTP1B, CD45, SHP-1, SHP-2, PTP alpha, LAR and HePTP or the like. The compounds are useful in the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, immune dysfunctions including autoimmunity diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of / or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases.

The invention discloses a magnetic coagulation mine water underground purification technology, relates to a method for carrying out a multistage treatment and purification on sewage generated in the mining industry, and aims to provides a purification technology having the advantages of capability of being carrying out in underground, short purification and separation time, little occupied space, little usage amount, low operation cost, and good purification effect. The technology comprises the following steps: converging the mine water to the front end of an underground central water chamber, filtering to remove the slag, introducing the water into a pre-precipitation tank, wherein in the pre-precipitation tank the sludge is periodically discharged into a sludge tank by a submerged sludge pump; introducing the water, which has been processed in the pre-precipitation tank, into a magnetic coagulation system, adding magnetic powder and a coagulating agent into the water, wherein in this process the suspended matters are transformed into micro floccules taking magnetic powder as the carriers; introducing the water into a magnetic separator after the coagulation, introducing the clean water into an underground water tank after the solid-liquid separation; transferring the coal sludge in the magnetic separator to a magnetic separating magnetic drum so as to absorb and recycle the magnetic powder, then discharging the coal sludge from which magnetic powder has been recycled into a sludge tank, and finally dehydrating the sludge in the sludge tank by a press filter so as to obtain dry sludge cakes.

An electromagnetic energy supply system for supplying electromagnetic energy signals to an applicator for applying the electromagnetic energy signals to tissue for heating such tissue can supply electromagnetic energy signals of at least one selected frequency of a plurality of frequencies available for selection. The system includes a plurality of individual electromagnetic signal generators each adapted to generate signals of a particular frequency, such as two microwave energy signal generators with one operating at 915 MHz and one operating at 1450 MHz. A system controller coordinates operation of the generators. Each generator is connected to connectors for connecting an applicator or array of applicators for applying the selected frequency electromagnetic energy signals to the tissue to be heated. A power splitting circuit can provide multiple connectors tuned for one or for more than one applicator to be connected. The system can provide a treatment using a single selected frequency, a plurality of selected frequencies simultaneously, or can switch between selected frequencies.

A system and process for continuously and immediately removing contaminants from wastewater and treating wastewater, where the wastewater is treated to supply fluid that can be reused in the cleaning system or discharged safely into the environment is disclosed. The system and method comprises one or more pumping means for circulating and recirculating fluids captured or collected by the system to one or more of the processes in the system, such as wash water applications or further treatment cycles. According to one embodiment, the wastewater is transported through purification sections of the device. Depending on the system used, these sections could include several of the following: pretreatment to remove debris and certain heavy solids; treatment by methods such as a conductivity solution injection system and / or electrolytic coagulation system, a polymer injection system, and a inline mixer for mixing the polymer in the wastewater stream; and an ozone treatment system. In a preferred embodiment, each of the treatment sections are contained within an enclosure cabinet that includes a controller and feed containers for conductivity fluid and polymers.

The multi-model dynamic matrix feeding amount control method for coagulation system in waterworks features that dynamic matrix predicting controller is constituted based on comprehensive multi-model dynamic matrix control theory and by means of using raw water flow rate as the control target, separating the whole system into several subspaces and separate experiments to obtain sectional linear models of the subspaces; and that outflow water turbidity is controlled through determining the dynamic model of the system, predicting the outflow water turbidity, weighting treatment to obtain overall control increment and regulating the feeding amount based on the current work conditions, practical water flow rate and certain weighting police. The present invention can ensure smooth outflow water turbidity, system running economic performance, high robustness and low cost.

The invention discloses an external circulation type pressurized dissolved air floatation-membrane separation water treatment method, which comprises the following steps that a. chemicals are added into wastewater to be treated, and coagulation reaction is completed through a coagulation system; b. wastewater subjected to coagulation enters an air floatation system to be subjected to partial backflow pressurized dissolved-air air floatation; and c. air floatation outlet water subjected to air floatation treatment enters a membrane separation system, and completes the membrane separation process under the effect of a membrane assembly, treated purified water and concentrated water are obtained, and the concentrated water obtained after membrane separation is injected into a dissolved air tank of the air floatation system in the step b from the bottom of a membrane separation pool for forming dissolved air water. The method provided by the invention has the advantages that the membrane pollution can be effectively relieved; the membrane flux is improved; in addition, the problem of low air floatation efficiency in the existing membrane-air floatation equipment is solved; the air floatation effect is more effectively realized; and the method and the device can be applicable to deep treatment of higher-concentration wastewater.

The invention concerns novel coagulation factor VII variants, wherein the Leu residue in position 305 or the Phe residue in position 374 of SEQ ID NO 1 has been replaced by another amino acid residue which can be encoded by nucleic acid constructs and, optionally, wherein at least one other amino acid residue in the remaining positions in the protease domain has been replaced by another amino acid residue which can be encoded by nucleic acid constructs;with the proviso that the variant is not FVII(Ala305).The invention further concerns nucleic acids encoding the Factor VII variants; vectors and cells comprising the nucleic acid; methods for producing the variants; pharmaceutical compositions comprising a Factor VII variant wherein the Leu residue in position 305 or the Phe residue in position 374 of SEQ ID NO 1 has been replaced by another amino acid residue which can be encoded by nucleic acid constructs and, optionally, wherein at least one other amino acid residue in the remaining positions in the protease domain has been replaced by another amino acid residue which can be encoded by nucleic acid constructs; use of the variants for producing a medicament for treatment or prophylaxis of bleeding disorders or enhancement of the coagulation system; and methods of treatment.

A coagulation system for the coagulation of organic tissue includes a laser configured to emit a working beam; an interrupter configured to at least partially interrupt the working beam; a controller configured to activate the interrupter; and a detector configured to detect a signal corresponding to a degree of coagulation or alteration of the tissue and to transmit a detection of the signal to the controller, the detector including a dimension meter.

The invention discloses a method for preparing anticoagulant polysulfone material by fourier reaction grafting, which comprises the steps of: introducing carboxyl into the polysulfone surface of through fourier reaction; then grafte polymerizing amino silane onto the carboxyl terminal to turn the polysulfone surface into silane, and finally combining anticoagulant medicament, as a covalent bond, to the amino end through a crosslinking agent so as to realize grafting anticoagulant medicament onto polysulfone surface and to obtain polysulfone material with excellent anticoagulant performance. The method is simple and rapid in process, and high in controllability. The material obtained has excellent anticoagulant performance, and may not disturb coagulation system of a body. The invention can be widely applied to the fields of extracorporeal circulation (e.g. artificial kidney), anticoagulant coating, biosensor, and bimolecular diagnosis and detection.

The invention relates to a multifield promotion-based coagulation and aggregation strengthening device and method for particulate matters. According to the coagulation and aggregation strengthening device, a heat-exchange cooling condenser, an ion wind-assisted orifice plate type electric coagulation system and a coagulation mixer are arranged in sequence in a coagulator, the ion wind-assisted orifice plate type electric coagulation system comprises an anode, orifice plate type polar plates and an cathode, the anode and the cathode are respectively arranged between two adjacent orifice plate type polar plates, a spray humidifier is also arranged in front of or behind the orifice plate type electric coagulation system, and the spray humidifier comprises a plurality of nozzles communicated with a liquid drop generating device. The coagulation and aggregation strengthening device combines phase change condensation with spray humidification and growth, simultaneously improves the particle collision and coagulation probability by using the ion wind convection field effect in an electric dust collector, and integrates multifield effects of electric field force, liquid bridge force, van der waals force, viscous force and the like in the same equipment for strengthening the coagulation and aggregation effects of the particles, so the average particle diameters of the particles are increased obviously, and the method is an efficient way for further increasing the removal effect of dedusting equipment and reducing the discharge concentration of particulate matters in flue gas.

The invention relates to a method for preparing a liquid porcellanite activating partial thromboplastin (APTT) reagent. The reagent is mainly used for monitoring coagulation factor deficiency of endogenous coagulation systems and carrying out screening test of related inhibitors, and used for detecting coagulation factors, heparin anticoagulation treatment and lupus anticoagulation substances as the current main means. Taking porcellanite as an activating agent, the method improves the sensitivity to the coagulation factors; a novel stable system solves the problem of keeping the stability of the reagent at a liquid state; and the method has the advantages of high sensitivity, convenient use, small experimental error, strong stability, good compatibility, low cost and the like.

An improved method of administration of an aptamer and antidote system to regulate blood coagulation in a host is provided based on weight adjusted or body mass index-adjusted dosing of the components of the system to provide a desired pharmacodynamic response. In addition, a method of reversing activity of the aptamer to a desired extent is provided where an antidote dose is based solely on its relationship to the aptamer dose.

The invention discloses a blood purification membrane with an anticoagulant property and a preparation method thereof. The blood purification membrane comprises a matrix, a polydopamine layer attachedto the surface of the substrate, argatroban grafted on the polydopamine layer and glutathione. The whole surface modification process is simple in experimental conditions, has strong controllability,and is economical and environmentally-friendly; the high-efficiency anti-coagulation on the local part of a material is realized; the blood coagulation system of a body is not affected; the blood compatibility is significantly improved; and the grafted anticoagulant drug argatroban has no antigenicity and does not cause heparin-induced thrombocytopenia.

There is provided a blood coagulation system analyzer, including a measurement section and an analysis section. The measurement section measures a time change of impedance of a blood sample, which is obtainable by applying an alternating electric field to the blood sample. The analysis section extracts a parameter indicating the characteristics of the impedance from the measured data of the time change of the impedance. Furthermore, the analysis section analyzes a degree of enhancement of blood coagulation on the basis of a comparison of the extracted parameter with at least one reference value which defines the criteria of the enhancement of blood coagulation.

The invention discloses a sewage treatment device for a large-scale sewage treatment station. The sewage treatment device comprises a filtering device, a regulating hydrolysis tank, a grade-A biochemical tank, a grade-O biochemical tank, a precipitation tank, an improved coagulation system, a disinfection tank, a sludge thickening tank, oxygenation equipment and a gas stripping device, wherein the filtering device, the regulating hydrolysis tank, the grade-A biochemical tank, the grade-O biochemical tank, the precipitation tank, the improved coagulation system and the disinfection tank are connected with one another in sequence from front to back; the gas stripping device is a pulse gas stripping device which is used for stripping one part of sludge precipitated in the precipitation tank into the sludge thickening tank, and the other part of the sludge precipitated in the precipitation tank into the grade-A biochemical tank; the grade-O biochemical tank is provided with the oxygenation equipment which is a centrifugal blower. The invention also provides a sewage treatment method for the large-scale sewage treatment station. The sewage treatment device disclosed by the invention has the advantages of being full in filtration and high in treatment efficiency of precipitated sludge, saving the floor area, and having an integrated function of regulation and decomposition.

An ultrasonic dissection and coagulation system for surgical use is provided. The system includes an ultrasonic instrument, a control module, and a remote actuator. The ultrasonic instrument has a housing and an elongated body portion extending from the housing. An ultrasonic transducer supported within the housing is operatively connected to a cutting jaw by a vibration coupler. The vibration coupler conducts high frequency vibration from the ultrasonic transducer to the cutting jaw. The cutting jaw has a blade surface which is curved downwardly and outwardly in the distal direction with respect to the longitudinal axis of the elongated body portion along its length such that an angle defined by a line drawn tangent to the blade surface and the longitudinal axis of the elongated body portion varies between 5 degrees and 75 degrees. A clamp member having a tissue contact surface is positioned adjacent to the cutting jaw and is movable from an open position in which the tissue contact surface is spaced form the blade surface to a clamped position in which the tissue contact surface is in close juxtaposed alignment with the blade surface to clamp tissue therebetween. The clamp member and the curved cutting jaw combine to enhance contact between tissue and the blade surface of the cutting jaw during cutting. Further, the continuously varying angle of the blade surface with respect to the longitudinal axis of the elongated body portion facilitates selective user control over the application of force on tissue during a cutting or dissecting procedure.

The invention discloses an aliphatic polycarbonate washing coagulation devolatilization method and a specific device thereof. The device according to the invention comprises: a polymerization kettle (1), a flash glue solution vessel, a coagulation system composed of more than one washing coagulation kettles (3), a solid-liquid separation system (4), a polymer drying system (5), a gear pump (6) and a connecting pipeline, wherein the polymerization kettle is provided with a product outlet at the lower part thereof and a gas outlet at the upper part thereof; the flash glue solution vessel is provided with an inlet and a gas outlet at the upper part thereof and a liquid outlet at the lower part thereof; and the washing coagulation kettle is provided with a washing coagulant inlet at the lower part thereof, a liquid inlet and a liquid outlet at the middle part thereof and a gas outlet at the upper part thereof. The method according to the invention has the advantages of: simple production technology, good suitability for automated control, continuous washing coagulation devolatilization; sufficient use of materials and energies, no gas-phase emptying in the process owing to the use of a closed vessel with pressure, very few solid-liquid wastes, complete ash removal and devolatilization of products, meeting the use demands in related fields, low industrial production cost and green chemistry standard-reaching industrialization process.

A system and process for continuously and immediately removing contaminants from wastewater and treating wastewater, where the wastewater is treated to supply fluid that can be reused in the cleaning system or discharged safely into the environment is disclosed. The system and method comprises one or more pumping means for circulating and recirculating fluids captured or collected by the system to one or more of the processes in the system, such as wash water applications or further treatment cycles. According to one embodiment, the wastewater is transported through purification sections of the device. Depending on the system used, these sections could include several of the following: pretreatment to remove debris and certain heavy solids; treatment by methods such as a conductivity solution injection system and / or electrolytic coagulation system, a polymer injection system, and a inline mixer for mixing the polymer in the wastewater stream; and an ozone treatment system. In a preferred embodiment, each of the treatment sections are contained within an enclosure cabinet that includes a controller and feed containers for conductivity fluid and polymers.

An ultrasonic dissection and coagulation system for surgical use is provided. The system includes an ultrasonic instrument, a control module, and a remote actuator. The ultrasonic instrument has a housing and an elongated body portion extending from the housing. An ultrasonic transducer supported within the housing is operatively connected to a cutting jaw by a vibration coupler. The vibration coupler conducts high frequency vibration from the ultrasonic transducer to the cutting jaw. The cutting jaw has a blade surface which is curved downwardly and outwardly in the distal direction with respect to the longitudinal axis of the elongated body portion along its length such that an angle defined by a line drawn tangent to the blade surface and the longitudinal axis of the elongated body portion varies between 5 degrees and 75 degrees. A clamp member having a tissue contact surface is positioned adjacent to the cutting jaw and is movable from an open position in which the tissue contact surface is spaced form the blade surface to a clamped position in which the tissue contact surface is in close juxtaposed alignment with the blade surface to clamp tissue therebetween. The clamp member and the curved cutting jaw combine to enhance contact between tissue and the blade surface of the cutting jaw during cutting. Further, the continuously varying angle of the blade surface with respect to the longitudinal axis of the elongated body portion facilitates selective user control over the application of force on tissue during a cutting or dissecting procedure.

Provided is a standalone integrated water treatment system for a distributed water supply including a filter input a coagulation system in operative connection with the filter input, wherein the water is subjected to a coagulation process to create pin floc from suspensions in the water. A maturation buffer tank in operative connection with the coagulation system aggregates floc in size within the water. A spiral separator separates the water into two water streams, a first stream of water having most of the floc removed, and a second stream of water which includes a concentrated amount of the floc. An optional filtration system is configured to receive the first stream of water and perform a filtration operation thereon. A sterilization system is configured to perform a sterilization operation on the first stream of water. The water is then output from the sterilization system as potable water.

The invention belongs to sewage treatment equipment, and particularly relates to a coagulation-floatation and co-coagulation solid-liquid separation device and a solid-liquid separation method. The separation device is characterized by being formed by sequentially installing a sewage medicating-mixing system, a multiphase medium pump air-dissolving system, a mixed reaction co-coagulation system and a co-coagulation solid-liquid separation device at a sewage pool; the separation device disclosed by the invention is reasonable in design and compact in structure, and provided with an independent mixed co-coagulation reaction and co-coagulation solid-liquid separation system; moreover, optimization for a coagulation-floatation and co-coagulation-floatation separation process is realized, and a variable-water-level dross removal method is used for dross removal; and the separation device has the characteristics of being simple and convenient, small in overall floor area, less in investment, high in efficiency, and the like. The separation device and the separation method are especially suitable for treating colloids and suspended matters in sewage and waste water generated during production and life processes, so as to realize solid-liquid separation.

The present invention relates to a stable solution comprising a stable solution without coagulation factor XII and with a defined amount of ionized calcium. The stable solution may be used as control material for coagulation analysis. Further, a method for producing said stable solution, as well as methods for assessing coagulation system status in a subject and kits, is encompassed herein.

The present invention provides novel compounds, novel compositions, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPase's) such as PTP1B, CD45, SHP-1, SHP-2, PTPα, LAR and HePTP or the like.The compounds are useful in the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, immune dysfunctions including autoimmunity diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of / or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases.